Daiken Biomedical Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Cash & Equivalents	5,433	2,236	1,140	287.07	243.71
Cash & Short-Term Investments	5,433	2,236	1,140	287.07	243.71
Cash Growth	355.90%	96.21%	297.03%	17.79%	-
Accounts Receivable	128	136.32	93.5	68.19	53.54
Other Receivables	11.88	7.27	0.65	3.33	-
Receivables	139.89	143.59	94.15	71.51	53.54
Inventory	428.05	416	245.71	262.65	178.36
Prepaid Expenses	43.24	41.41	31.89	19.39	17.58
Other Current Assets	1.12	3,026	-	92.12	30.71
Total Current Assets	6,046	5,863	1,511	732.73	523.9
Property, Plant & Equipment	18.29	19.25	3.28	-	-
Other Intangible Assets	3.7	3.96	3.74	1.46	1.09
Long-Term Deferred Tax Assets	14.9	13.07	11.69	6.53	-
Other Long-Term Assets	33.38	13.3	7.62	4.45	5.18
Total Assets	6,116	5,913	1,538	745.17	530.17
Accounts Payable	116.69	154.33	73.75	53.15	32.4
Accrued Expenses	1.06	80.7	63.24	89.3	87.6
Short-Term Debt	100	100	-	158	33
Current Portion of Long-Term Debt	-	-	-	69.02	41.63
Current Portion of Leases	3.22	3.2	1.82	-	-
Current Income Taxes Payable	101.39	63.92	9.37	28.15	19.36
Current Unearned Revenue	10.53	10.18	7.26	30.23	21.46
Other Current Liabilities	220.43	34.54	74.93	20.45	5.91
Total Current Liabilities	553.32	446.87	230.37	448.29	241.37
Long-Term Debt	-	-	-	49.56	61.37
Long-Term Leases	14.37	15.18	0.45	-	-
Long-Term Deferred Tax Liabilities	30.22	7.9	-	-	-
Total Liabilities	597.91	469.95	230.81	497.85	302.74
Common Stock	810.02	810.02	600.02	155.4	155.4
Additional Paid-In Capital	4,415	4,415	624.06	-	-
Retained Earnings	172.04	187.38	83.76	91.92	72.03
Comprehensive Income & Other	120.88	30.35	-0.86	-	-
Shareholders' Equity	5,518	5,443	1,307	247.32	227.43
Total Liabilities & Equity	6,116	5,913	1,538	745.17	530.17
Total Debt	117.58	118.37	2.27	276.58	136
Net Cash (Debt)	5,316	2,118	1,137	10.49	107.71
Net Cash Growth	346.57%	86.20%	10746.37%	-90.26%	-
Net Cash Per Share	6.56	3.17	2.59	0.05	0.69
Filing Date Shares Outstanding	810.02	810.02	600.02	155.4	155.4
Total Common Shares Outstanding	810.02	810.02	600.02	155.4	155.4
Working Capital	5,492	5,416	1,281	284.44	282.53
Book Value Per Share	6.81	6.72	2.18	1.59	1.46
Tangible Book Value	5,514	5,439	1,303	245.86	226.34
Tangible Book Value Per Share	6.81	6.71	2.17	1.58	1.46

Source: S&P Global Market Intelligence. Standard template. Financial Sources.